Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.58 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | DUT | P33316 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | LPL | P06858 | 1/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14788223 | 0.92 | FFAR1 (0.55) | FFAR1DGAT1DUTLPLLIPG | |
| SCHEMBL25289998 | 0.90 | FFAR1 (0.53) | FFAR1DGAT1DUTLPLLIPG | |
| SCHEMBL20026953 | 0.86 | FFAR1 (0.60) | FFAR1DGAT1IRAK4AAK1LPL | |
| SCHEMBL16610714 | 0.83 | FFAR1 (0.51) | FFAR1DGAT1IRAK4LPLLIPG | |
| SCHEMBL21092774 | 0.82 | FFAR1 (0.62) | FFAR1DGAT1AAK1 | |
| SCHEMBL253540 | 0.82 | FFAR1 (0.57) | FFAR1DGAT1IRAK4LPLLIPG | |
| SCHEMBL15283735 | 0.80 | FFAR1 (0.53) | FFAR1DGAT1AAK1 | |
| SCHEMBL9286866 | 0.80 | FFAR1 (0.53) | FFAR1DGAT1AAK1 | |
| SCHEMBL20916372 | 0.80 | FFAR1 (0.56) | FFAR1DGAT1IRAK4AAK1LPL | |
| SCHEMBL3004343 | 0.80 | FFAR1 (0.55) | FFAR1DGAT1IRAK4LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325550-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORP (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250289823-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | INCYTE CORPORATION | 2025-09-18 | — | — | US | disclosed |
| US-20250270190-A1 | KIT INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-08-28 | — | — | US | disclosed |
| EP-3947366-B1 | HPK1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-21 | — | — | EP | disclosed |
| EP-3888657-B1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORP (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4511366-A1 | KIT INHIBITORS | Blueprint Medicines Corporation (US) | 2025-02-26 | — | — | EP | disclosed |
| US-12201636-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-12152033-B2 | Use of pyrazolopyrimidine derivatives for the treatment of PI3K-δ related disorders | INCYTE CORPORATION (US) | 2024-11-26 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| WO-2014134426-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS | INCYTE CORPORATION (US) | 2014-09-04 | — | — | WO | disclosed |
| US-20130244999-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130244999-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130244999-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2013-09-19 | — | — | US | disclosed |
| US-8436008-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-05-07 | — | — | US | disclosed |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | US | disclosed |
| EP-2379523-A1 | 4, 6-DISUBSTITUTED 2-AMINO-PYRIMIDINES AS HISTAMINE H4 RECEPTOR MODULATORS | Incyte Corporation (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20100173901-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2010-07-08 | — | — | US | disclosed |
| WO-2010075270-A1 | 4, 6-DISUBSTITUTED 2-AMINO-PYRIMIDINES AS HISTAMINE H4 RECEPTOR MODULATORS | INCYTE CORPORATION (US) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325550-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | FFAR1 3228/4885DGAT1 2457/4885DUT 2170/4885 |
| US-20100173901-A1 | Substituted Heterocyclic Compounds | HRH4, HRH2, HRH1 | FFAR1 285/4885DGAT1 4006/4885DUT 2924/4885 |
| US-20130244999-A1 | Substituted Heterocyclic Compounds | HRH4, HRH2, HRH1 | FFAR1 285/4885DGAT1 4006/4885DUT 2924/4885 |
| US-12152033-B2 | Use of pyrazolopyrimidine derivatives for the treatment of PI3K-δ related disorders | PIK3CD, PIK3CA, PIK3R5 | FFAR1 2580/4885DGAT1 1750/4885DUT 4387/4885 |
| US-20250270190-A1 | KIT INHIBITORS | KIT, ABL1, APC | FFAR1 3730/4885DGAT1 4407/4885DUT 2341/4885 |
| US-20250289823-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | PIK3CD, PIK3CA, PIK3CB | FFAR1 2643/4885DGAT1 1616/4885DUT 4164/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | FFAR1 4787/4885DGAT1 1563/4885DUT 1888/4885 |
| US-12201636-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | FFAR1 3228/4885DGAT1 2457/4885DUT 2170/4885 |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | FFAR1 3228/4885DGAT1 2457/4885DUT 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.